Masood Khan joins KCAS team

Becomes senior director of ligand binding assay services

KCAS, a US bioanalytical laboratory specialising in research and analytical services for pharmaceutical, biotech, animal health and medical device companies, has added Masood Khan to its growing team of experts. He will serve as senior director of ligand binding assay (LBA) services.

For nearly 20 years, Dr Khan has led wide-ranging research on strategic planning for LBA programmes, as well as the development of GLP-compliant and non-GLP assays for the conduct of ligand binding studies. He has chaired and organised many conferences and lectures at annual forums and meetings of the American Association of Pharmaceutical Scientists’ (AAPS) and has helped establish the LBAB-Focus Group, a specialist division of AAPS.

Dr Khan has worked in executive capacities for several contract research organisations (CROs) and pharmaceutical companies including MDS Life Sciences, Covance, NeuroBiotech, Medlmmune and most recently the National Institute of Health.

Dr Khan received his PhD in biochemistry from Aligarh University, India, and has conducted post-doctoral studies at the National Institute of Environmental Health Sciences in North Carolina and McGill University, Royal Victoria Hospital in Canada.

You may also like

Research & Development

Dual inhibition of motor proteins KIF18A and CENP-E shown to selectively kill cancer cells

Researchers from Osaka University and MIT have discovered that blocking two cooperative motor proteins involved in chromosome alignment can trigger cancer cell death, revealing a promising new target for anticancer therapies
Research & Development

EVerZom and GENFIT partner for research collaboration for liver failure candidate EViv

The agreement will support EVerZom’s dynamic development strategy and follows the recent announcement of a €10m financing round aimed at accelerating its clinical and partnering roadmap
Manufacturing

Watson-Marlow to showcase advanced fluid path solutions at COMPAMED 2025

The fluid transfer solution specialist will highlight a variety of peristaltic pumps and associated fluid path technologies at this years COMPAMED 2025, taking place from 17-20 Nov in Düsseldorf, Germany
Research & Development

Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development

Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies
You need to be a subscriber to read this article.
Click here to find out more.
Personal Protection

Gas safety in smaller pharmaceutical facilities

Whether in the production process, for essential sterilisation or decontamination, the use of gases is fundamental in the pharmaceutical and biopharmaceutical industries. Each gas is, however, accompanied by risks and can pose significant hazards to the health of employees
Sustainability

Guardtech supporting malaria fight in East Africa with portable 11-bay lab

Suffolk-based experts provide Cleancube Multi 11 for Oxitec’s Friendly mosquito programme in Djibouti
Ingredients

Optimising sample traceability with laser marking technology

Speed and precision in high-throughput tube identification
Subscribe now